226 related articles for article (PubMed ID: 18497862)
1. BRCA1 and BRCA2 missense variants of high and low clinical significance influence lymphoblastoid cell line post-irradiation gene expression.
Waddell N; Ten Haaf A; Marsh A; Johnson J; Walker LC; ; Gongora M; Brown M; Grover P; Girolami M; Grimmond S; Chenevix-Trench G; Spurdle AB
PLoS Genet; 2008 May; 4(5):e1000080. PubMed ID: 18497862
[TBL] [Abstract][Full Text] [Related]
2. Use of DNA-damaging agents and RNA pooling to assess expression profiles associated with BRCA1 and BRCA2 mutation status in familial breast cancer patients.
Walker LC; Thompson BA; Waddell N; ; Grimmond SM; Spurdle AB
PLoS Genet; 2010 Feb; 6(2):e1000850. PubMed ID: 20174566
[TBL] [Abstract][Full Text] [Related]
3. Cyclin D1 expression analysis in familial breast cancers may discriminate BRCAX from BRCA2-linked cases.
Colombo M; Giarola M; Mariani L; Ripamonti CB; De Benedetti V; Sardella M; Losa M; Manoukian S; Peissel B; Pierotti MA; Pilotti S; Radice P
Mod Pathol; 2008 Oct; 21(10):1262-70. PubMed ID: 18327210
[TBL] [Abstract][Full Text] [Related]
4. Prediction of BRCA1 and BRCA2 mutation status using post-irradiation assays of lymphoblastoid cell lines is compromised by inter-cell-line phenotypic variability.
Lovelock PK; Wong EM; Sprung CN; Marsh A; Hobson K; French JD; Southey M; Sculley T; Pandeya N; Brown MA; Chenevix-Trench G; Spurdle AB; McKay MJ;
Breast Cancer Res Treat; 2007 Sep; 104(3):257-66. PubMed ID: 17063265
[TBL] [Abstract][Full Text] [Related]
5. Use of expression data and the CGEMS genome-wide breast cancer association study to identify genes that may modify risk in BRCA1/2 mutation carriers.
Walker LC; Waddell N; Ten Haaf A; ; Grimmond S; Spurdle AB
Breast Cancer Res Treat; 2008 Nov; 112(2):229-36. PubMed ID: 18095154
[TBL] [Abstract][Full Text] [Related]
6. Accurate prediction of BRCA1 and BRCA2 heterozygous genotype using expression profiling after induced DNA damage.
Kote-Jarai Z; Matthews L; Osorio A; Shanley S; Giddings I; Moreews F; Locke I; Evans DG; Eccles D; ; Williams RD; Girolami M; Campbell C; Eeles R
Clin Cancer Res; 2006 Jul; 12(13):3896-901. PubMed ID: 16818684
[TBL] [Abstract][Full Text] [Related]
7. Determination of molecular markers for BRCA1 and BRCA2 heterozygosity using gene expression profiling.
Salmon AY; Salmon-Divon M; Zahavi T; Barash Y; Levy-Drummer RS; Jacob-Hirsch J; Peretz T
Cancer Prev Res (Phila); 2013 Feb; 6(2):82-90. PubMed ID: 23341570
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of the contribution of germline variants in BRCA1 and BRCA2 to uveal and cutaneous melanoma.
Johansson PA; Nathan V; Bourke LM; Palmer JM; Zhang T; Symmons J; Howlie M; Patch AM; Read J; Holland EA; Schmid H; Warrier S; Glasson W; Höiom V; Wadt K; Jönsson G; Olsson H; Ingvar C; Mann G; Brown KM; Hayward NK; Pritchard AL
Melanoma Res; 2019 Oct; 29(5):483-490. PubMed ID: 31464824
[TBL] [Abstract][Full Text] [Related]
9. Molecular insights into the OGG1 gene, a cancer risk modifier in BRCA1 and BRCA2 mutations carriers.
Benitez-Buelga C; Vaclová T; Ferreira S; Urioste M; Inglada-Perez L; Soberón N; Blasco MA; Osorio A; Benitez J
Oncotarget; 2016 May; 7(18):25815-25. PubMed ID: 27015555
[TBL] [Abstract][Full Text] [Related]
10. Molecular classification of familial non-BRCA1/BRCA2 breast cancer.
Hedenfalk I; Ringner M; Ben-Dor A; Yakhini Z; Chen Y; Chebil G; Ach R; Loman N; Olsson H; Meltzer P; Borg A; Trent J
Proc Natl Acad Sci U S A; 2003 Mar; 100(5):2532-7. PubMed ID: 12610208
[TBL] [Abstract][Full Text] [Related]
11. Enhanced RAD21 cohesin expression confers poor prognosis in BRCA2 and BRCAX, but not BRCA1 familial breast cancers.
Yan M; Xu H; Waddell N; Shield-Artin K; Haviv I; ; McKay MJ; Fox SB
Breast Cancer Res; 2012 Apr; 14(2):R69. PubMed ID: 22537934
[TBL] [Abstract][Full Text] [Related]
12. Phenotypic analysis of familial breast cancer: comparison of BRCAx tumors with BRCA1-, BRCA2-carriers and non-familial breast cancer.
Aloraifi F; Alshehhi M; McDevitt T; Cody N; Meany M; O'Doherty A; Quinn CM; Green AJ; Bracken A; Geraghty JG
Eur J Surg Oncol; 2015 May; 41(5):641-6. PubMed ID: 25736863
[TBL] [Abstract][Full Text] [Related]
13. Searching for candidate genes in familial BRCAX mutation carriers with prostate cancer.
Hunter SM; Rowley SM; Clouston D; ; Li J; Lupat R; Krishnananthan N; Risbridger G; Taylor R; Bolton D; Campbell IG; Thorne H
Urol Oncol; 2016 Mar; 34(3):120.e9-16. PubMed ID: 26585945
[TBL] [Abstract][Full Text] [Related]
14. miRNA expression profiling of hereditary breast tumors from BRCA1- and BRCA2-germline mutation carriers in Brazil.
Pessôa-Pereira D; Evangelista AF; Causin RL; da Costa Vieira RA; Abrahão-Machado LF; Santana IVV; da Silva VD; de Souza KCB; de Oliveira-Silva RJ; Fernandes GC; Reis RM; Palmero EI; Marques MMC
BMC Cancer; 2020 Feb; 20(1):143. PubMed ID: 32087690
[TBL] [Abstract][Full Text] [Related]
15. A predictor based on the somatic genomic changes of the BRCA1/BRCA2 breast cancer tumors identifies the non-BRCA1/BRCA2 tumors with BRCA1 promoter hypermethylation.
Alvarez S; Diaz-Uriarte R; Osorio A; Barroso A; Melchor L; Paz MF; Honrado E; Rodríguez R; Urioste M; Valle L; Díez O; Cigudosa JC; Dopazo J; Esteller M; Benitez J
Clin Cancer Res; 2005 Feb; 11(3):1146-53. PubMed ID: 15709182
[TBL] [Abstract][Full Text] [Related]
16. DNA repair-related functional assays for the classification of BRCA1 and BRCA2 variants: a critical review and needs assessment.
Toland AE; Andreassen PR
J Med Genet; 2017 Nov; 54(11):721-731. PubMed ID: 28866612
[TBL] [Abstract][Full Text] [Related]
17. Histopathological features of 'BRCAX' familial breast cancers in the kConFab resource.
Loughrey M; Provan PJ; Byth K; ; Balleine RL
Pathology; 2008 Jun; 40(4):352-8. PubMed ID: 18446624
[TBL] [Abstract][Full Text] [Related]
18. Classifications within molecular subtypes enables identification of BRCA1/BRCA2 mutation carriers by RNA tumor profiling.
Larsen MJ; Kruse TA; Tan Q; Lænkholm AV; Bak M; Lykkesfeldt AE; Sørensen KP; Hansen TV; Ejlertsen B; Gerdes AM; Thomassen M
PLoS One; 2013; 8(5):e64268. PubMed ID: 23704984
[TBL] [Abstract][Full Text] [Related]
19. Clinical and molecular characterization of the BRCA2 p.Asn3124Ile variant reveals substantial evidence for pathogenic significance.
Surowy HM; Sutter C; Mittnacht M; Klaes R; Schaefer D; Evers C; Burgemeister AL; Goehringer C; Dikow N; Heil J; Golatta M; Schott S; Schneeweiss A; Bugert P; Sohn C; Bartram CR; Burwinkel B
Breast Cancer Res Treat; 2014 Jun; 145(2):451-60. PubMed ID: 24728577
[TBL] [Abstract][Full Text] [Related]
20. Transcriptional signature of lymphoblastoid cell lines of
Pouliot MC; Kothari C; Joly-Beauparlant C; Labrie Y; Ouellette G; Simard J; Droit A; Durocher F
Oncotarget; 2017 Oct; 8(45):78691-78712. PubMed ID: 29108258
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
